165 related articles for article (PubMed ID: 36661721)
1. Effect of Different Durations of Adjuvant Capecitabine Monotherapy on the Outcome of High-Risk Stage II and Stage III Colorectal Cancer: A Retrospective Study Based on a CRC Database.
Yu Q; Li Z; Liu Y; Luo Y; Fan J; Xie P; Cao X; Chen X; Wang X
Curr Oncol; 2023 Jan; 30(1):949-958. PubMed ID: 36661721
[TBL] [Abstract][Full Text] [Related]
2. Phase III randomised trial comparing 6 vs. 12-month of capecitabine as adjuvant chemotherapy for patients with stage III colon cancer: final results of the JFMC37-0801 study.
Tomita N; Kunieda K; Maeda A; Hamada C; Yamanaka T; Sato T; Yoshida K; Boku N; Nezu R; Yamaguchi S; Mishima H; Sadahiro S; Muro K; Ishiguro M; Sakamoto J; Saji S; Maehara Y
Br J Cancer; 2019 Apr; 120(7):689-696. PubMed ID: 30833647
[TBL] [Abstract][Full Text] [Related]
3. Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JSWOG-C2 study.
Tsuruta A; Yamashita K; Tanioka H; Tsuji A; Inukai M; Yamakawa T; Yamatsuji T; Yoshimitsu M; Toyota K; Yamano T; Nagasaka T; Okajima M
Drug Des Devel Ther; 2016; 10():3827-3835. PubMed ID: 27920498
[TBL] [Abstract][Full Text] [Related]
4. Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial.
Petrelli F; Labianca R; Zaniboni A; Lonardi S; Galli F; Rulli E; Rosati G; Corallo S; Ronzoni M; Cardellino GG; Mattioli R; Mambrini A; Ciuffreda L; Banzi M; Pusceddu V; Maiello E; Zampino M; Zagonel V; Marchetti P; Corsi D; Rimassa L; Cinieri S; Sobrero A
JAMA Oncol; 2020 Apr; 6(4):547-551. PubMed ID: 32053133
[TBL] [Abstract][Full Text] [Related]
5. Prolonged Capecitabine Chemotherapy Following Capecitabine and Oxaliplatin (CAPOX) Regimen Chemotherapy Failed to Improve Survival of Stage III Colorectal Cancer After Radical Resection.
Xu JL; Tang CW; Feng WM; Bao Y; Chai ZZ
Med Sci Monit; 2019 Jun; 25():4831-4836. PubMed ID: 31254462
[TBL] [Abstract][Full Text] [Related]
6. Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer: A Secondary Analysis of the AVANT Trial.
Chibaudel B; Henriques J; Rakez M; Brenner B; Kim TW; Martinez-Villacampa M; Gallego-Plazas J; Cervantes A; Shim K; Jonker D; Guerin-Meyer V; Mineur L; Banzi C; Dewdney A; Dejthevaporn T; Bloemendal HJ; Roth A; Moehler M; Aranda E; Van Cutsem E; Tabernero J; Schmoll HJ; Hoff PM; André T; de Gramont A
JAMA Netw Open; 2020 Oct; 3(10):e2020425. PubMed ID: 33074326
[TBL] [Abstract][Full Text] [Related]
7. Capecitabine versus S-1 as adjuvant chemotherapy for patients with stage III colorectal cancer (JCOG0910): an open-label, non-inferiority, randomised, phase 3, multicentre trial.
Hamaguchi T; Shimada Y; Mizusawa J; Kinugasa Y; Kanemitsu Y; Ohue M; Fujii S; Takiguchi N; Yatsuoka T; Takii Y; Ojima H; Masuko H; Kubo Y; Mishima H; Yamaguchi T; Bando H; Sato T; Kato T; Nakamura K; Fukuda H; Moriya Y
Lancet Gastroenterol Hepatol; 2018 Jan; 3(1):47-56. PubMed ID: 29079411
[TBL] [Abstract][Full Text] [Related]
8. Low-dose capecitabine adjuvant chemotherapy in elderly stage II/III colorectal cancer patients (LC-ACEC): study protocol for a randomized controlled trial.
He Y; Liu P; Zhang Y; Deng X; Meng W; Wei M; Yang T; Wang Z; Qiu M
Trials; 2015 May; 16():238. PubMed ID: 26021722
[TBL] [Abstract][Full Text] [Related]
9. Three- versus six-month adjuvant FOLFOX or CAPOX for high-risk stage II and stage III colon cancer patients: the efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) project.
Souglakos J; Boukovinas I; Kakolyris S; Xynogalos S; Ziras N; Athanasiadis A; Androulakis N; Christopoulou A; Vaslamatzis M; Ardavanis A; Emmanouilides C; Bompolaki I; Kourousis C; Makrantonakis P; Christofyllakis C; Athanasiadis E; Kentepozidis N; Karampeazis A; Katopodi U; Anagnosopoulos A; Papadopoulos G; Prinarakis E; Kalisperi A; Mavroudis D; Georgoulias V
Ann Oncol; 2019 Aug; 30(8):1304-1310. PubMed ID: 31228203
[TBL] [Abstract][Full Text] [Related]
10. Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or stage III colorectal cancer.
Pectasides D; Karavasilis V; Papaxoinis G; Gourgioti G; Makatsoris T; Raptou G; Vrettou E; Sgouros J; Samantas E; Basdanis G; Papakostas P; Bafaloukos D; Kotoula V; Kalofonos HP; Scopa CD; Pentheroudakis G; Fountzilas G
BMC Cancer; 2015 May; 15():384. PubMed ID: 25956750
[TBL] [Abstract][Full Text] [Related]
11. [Study of the Postoperative Adjuvant Chemotherapy with UFT/LV or Capecitabine for Stage III Colorectal Cancer].
Maruyama T; Yasuda K; Sako A; Ueda K; Okumura M
Gan To Kagaku Ryoho; 2016 Jan; 43(1):69-72. PubMed ID: 26809528
[TBL] [Abstract][Full Text] [Related]
12. Impact of tumor deposits on the prognosis and chemotherapy efficacy in stage III colorectal cancer patients with different lymph node status: A retrospective cohort study in China.
Li X; An B; Zhao Q; Qi J; Wang W; Zhang D; Li Z; Qin C
Int J Surg; 2018 Aug; 56():188-194. PubMed ID: 29936197
[TBL] [Abstract][Full Text] [Related]
13. Oxaliplatin (3 months
Kim ST; Kim SY; Lee J; Yun SH; Kim HC; Lee WY; Kim TW; Hong YS; Lim SB; Baek JY; Oh JH; Ahn JB; Shin SJ; Han SW; Kim SG; Kang SY; Sym SJ; Zang DY; Kim YH; Choi IS; Kang JH; Kim MJ; Park YS
J Clin Oncol; 2022 Nov; 40(33):3868-3877. PubMed ID: 35772045
[TBL] [Abstract][Full Text] [Related]
14. Recurrence-free and overall survival among elderly stage III colon cancer patients treated with CAPOX or capecitabine monotherapy.
van Erning FN; Janssen-Heijnen ML; Creemers GJ; Pruijt JF; Maas HA; Lemmens VE
Int J Cancer; 2017 Jan; 140(1):224-233. PubMed ID: 27615021
[TBL] [Abstract][Full Text] [Related]
15. The influence of PD-L1 genetic variation on the prognosis of R0 resection colorectal cancer patients received capecitabine-based adjuvant chemotherapy: a long-term follow-up, real-world retrospective study.
Su J; Dai B; Yuan W; Wang G; Zhang Z; Li Z; Liu J; Song J
Cancer Chemother Pharmacol; 2020 May; 85(5):969-978. PubMed ID: 32314029
[TBL] [Abstract][Full Text] [Related]
16. 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial.
Iveson TJ; Kerr RS; Saunders MP; Cassidy J; Hollander NH; Tabernero J; Haydon A; Glimelius B; Harkin A; Allan K; McQueen J; Scudder C; Boyd KA; Briggs A; Waterston A; Medley L; Wilson C; Ellis R; Essapen S; Dhadda AS; Harrison M; Falk S; Raouf S; Rees C; Olesen RK; Propper D; Bridgewater J; Azzabi A; Farrugia D; Webb A; Cunningham D; Hickish T; Weaver A; Gollins S; Wasan HS; Paul J
Lancet Oncol; 2018 Apr; 19(4):562-578. PubMed ID: 29611518
[TBL] [Abstract][Full Text] [Related]
17. Oncologic outcomes after adjuvant chemotherapy with capecitabine compared to 5-fluorouracil/leucovorin for geriatric stage II colon cancer: a retrospective cohort study.
Lee KY; Park JW; Lee KY; Cho S; Kwon YH; Kim MJ; Ryoo SB; Jeong SY; Park KJ
Int J Colorectal Dis; 2019 Apr; 34(4):629-639. PubMed ID: 30661101
[TBL] [Abstract][Full Text] [Related]
18. [Effect of Chinese materia medica combined chemotherapy on the survivals of stage II and III colorectal cancer].
Lu XM; Zheng J; Zhu YJ
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2012 Sep; 32(9):1166-70. PubMed ID: 23185751
[TBL] [Abstract][Full Text] [Related]
19. Survival analysis of elderly patients over 65 years old with stage II/III gastric cancer treated with adjuvant chemotherapy after laparoscopic D2 gastrectomy: a retrospective cohort study.
Liang Y; Zhao L; Chen H; Lin T; Chen T; Zhao M; Hu Y; Yu J; Liu H; Li G
BMC Cancer; 2021 Feb; 21(1):196. PubMed ID: 33632161
[TBL] [Abstract][Full Text] [Related]
20. Predictive value of pretreatment lymphocyte count in stage II colorectal cancer and in high-risk patients treated with adjuvant chemotherapy.
Liang L; Zhu J; Jia H; Huang L; Li D; Li Q; Li X
Oncotarget; 2016 Jan; 7(1):1014-28. PubMed ID: 26510910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
